Leif Johansson, Non-executive chairman of AstraZeneca
End of an era at AstraZeneca as Leif Johansson preps exit as chairman. So where does that leave Soriot?
When Leif Johansson took the chairman’s spot at AstraZeneca in 2012, the company was a mess. David Brennan had just been pushed out of the CEO’s job. The pipeline was easily the worst in Big Pharma. And they needed a new CEO who could begin to put things back together.
To top it all off, Pfizer would soon come calling with an offer to buy out the company for $118 billion — and quite a few of its investors thought that looked pretty sweet.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
